InspireMD Reports First Quarter 2025 Financial Results
- Revenue increased 1.2% year-over-year to $1.53 million
- Continued progress with FDA for CGuard Prime approval expected in Q3 2025
- Strong cash position of $26.09 million
- Advanced commercial infrastructure and sales force expansion for U.S. launch
- Net loss widened to $11.17 million from $7.03 million year-over-year
- Operating expenses increased 52.5% to $11.75 million
- Financial income decreased 23% to $294,000
- Cash position decreased from $34.64 million to $26.09 million quarter-over-quarter
Insights
InspireMD shows modest revenue growth but substantially widening losses as it prepares for potential CGuard Prime FDA approval in Q3 2025.
InspireMD's Q1 2025 results reveal a company in transition phase, with minimal revenue growth of just
The dramatic operating expense increase of
Most concerning is the rapid cash burn rate. Cash and marketable securities decreased by
The entire strategic bet centers on FDA approval in Q3 2025. Management appears confident about approval prospects despite acknowledging "dynamics within the agency" and audit timing issues. The CGUARDIANS II pivotal study continues enrolling patients at "excellent pace," supporting the company's TCAR (Transcarotid Artery Revascularization) procedure strategy.
This quarter represents classic pre-commercialization financial dynamics - significant investment preceding anticipated regulatory approval, with intentional cost increases designed to enable rapid market penetration following approval. The key question remains whether CGuard Prime will generate sufficient US market adoption to justify the current cash burn and create a path to profitability.
Management to host investor conference call today, May 9th, at 8:30am ET
MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2025.
Business Highlights:
- Continued engagement with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent system in the U.S. Optimistic for an anticipated approval in the third quarter of 2025
- Advanced commercial infrastructure and operational readiness ahead of anticipated U.S. launch
- Continued enrollment with excellent pace in the CGUARDIANS II pivotal study of the CGuard Prime carotid stent system for use during TCAR procedures
Marvin Slosman, CEO of InspireMD, commented: “In the first quarter we continued to drive commercial adoption of our technology in our served markets, while laying a strong operational and strategic foundation for upcoming transformational milestones. With a clear roadmap for commercial expansion and a disciplined focus on execution, we’ve built and trained a world-class commercial team—ready to execute at scale upon potential FDA PMA approval. We’re energized by the momentum and confident in the opportunities on the horizon.”
“We continue to work interactively with the FDA and are optimistic for an anticipated approval of CGuard Prime in the third quarter of 2025. Despite dynamics within the agency and the timing of our audit in February, we are confident the remaining items will be successfully completed. I am excited about the transformative milestones ahead as we work to bring this innovative technology to patients in the U.S. and drive the next chapter of InspireMD’s growth,” Mr. Slosman concluded.
Financial Results for the First Quarter Ended March 31, 2025
For the first quarter of 2025, total revenue increased by
Gross profit for the first quarter of 2025 remained constant at
Total operating expenses for the first quarter of 2025 were
Financial income, net for the first quarter of 2025 was
Net loss for the first quarter of 2025 totaled
As of March 31, 2025, cash and cash equivalents and marketable securities were
Conference Call and Webcast Details
Management will host a conference call at 8:30 am ET today, May 9th, to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session.
| Friday, May 9th at 8:30 a.m. ET | |||
| Domestic: | 1-800-579-2543 | ||
| International: | 1-785-424-1789 | ||
| Conference ID: | IMD1Q25 | ||
| Webcast: | Webcast Link – Click Here | ||
| https://viavid.webcasts.com/starthere.jsp?ei=1713642&tp_key=1c3c464032 | |||
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR.
We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.
Forward-looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation, including potential FDA approval and potential U.S. commercial launch. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with our history of recurring losses and negative cash flows from operating activities; substantial doubt about our ability to continue as a going concern; significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; our need to raise additional capital to meet our business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute out stockholders’ ownership interests; market acceptance of our products; an inability to secure and maintain regulatory approvals for the sale of our products; negative clinical trial results or lengthy product delays in key markets; our ability to maintain compliance with the Nasdaq listing standards; our ability to generate revenues from our products and obtain and maintain regulatory approvals for our products; our ability to adequately protect our intellectual property; our dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our technology is an attractive alternative to other procedures and products; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; entry of new competitors and products and potential technological obsolescence of our products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with our research and products and potential product liability claims; product malfunctions; price increases for supplies and components; insufficient or inadequate reimbursement by governmental and other third-party payers for our products; our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; the escalation of hostilities in Israel, which could impair our ability to manufacture our products; and current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts:
Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
craigs@inspiremd.com
Webb Campbell
Gilmartin Group LLC
Webb@gilmartinir.com
investor-relations@inspiremd.com
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(1) (U.S. dollars in thousands, except share and per share data) | |||||||
| Three months ended | |||||||
| March 31, | |||||||
| 2025 | 2024 | ||||||
| Revenues | $ | 1,529 | $ | 1,511 | |||
| Cost of revenues | 1,237 | 1,219 | |||||
| Gross Profit | 292 | 292 | |||||
| Operating Expenses: | |||||||
| Research and development | 4,059 | 2,625 | |||||
| Selling and marketing | 2,750 | 1,237 | |||||
| General and administrative | 4,943 | 3,844 | |||||
| Total operating expenses | 11,752 | 7,706 | |||||
| Loss from operations | (11,460 | ) | (7,414 | ) | |||
| Financial Income, net | 294 | 382 | |||||
| Net Loss | $ | (11,166 | ) | $ | (7,032 | ) | |
| Net loss per share – basic and diluted | $ | (0.22 | ) | $ | (0.21 | ) | |
| Weighted average number of shares of common stock used in computing net loss per share – basic and diluted | 49,993,509 | 34,242,976 | |||||
| CONDENSED CONSOLIDATED BALANCE SHEETS(2) | |||||||
| (U.S. dollars in thousands, except share and per share data) | |||||||
| ASSETS | March 31, | December 31, | |||||
| 2025 | 2024 | ||||||
| Current Assets: | |||||||
| Cash and cash equivalents | $ | 12,383 | $ | 18,916 | |||
| Marketable securities | 13,703 | 15,721 | |||||
| Accounts receivable: | |||||||
| Trade, net | 1,580 | 1,572 | |||||
| Other | 763 | 682 | |||||
| Prepaid expenses | 893 | 1,060 | |||||
| Inventory | 2,822 | 2,570 | |||||
| Total current assets | 32,144 | 40,521 | |||||
| Non-current assets: | |||||||
| Long term deposit | 430 | 426 | |||||
| Property, plant and equipment, net | 2,736 | 2,371 | |||||
| Operating lease right of use assets | 2,225 | 2,360 | |||||
| Funds in respect of employee rights upon retirement | 1,137 | 1,129 | |||||
| Total non-current assets | 6,528 | 6,286 | |||||
| Total assets | $ | 38,672 | $ | 46,807 | |||
| LIABILITIES AND EQUITY | March 31, | December 31, | |||||
| 2025 | 2024 | ||||||
| Current liabilities: | |||||||
| Accounts payable and accruals: | |||||||
| Trade | $ | 1,727 | $ | 1,254 | |||
| Other | 5,640 | 6,424 | |||||
| Total current liabilities | 7,367 | 7,678 | |||||
| Long-term liabilities: | |||||||
| Operating lease liabilities net of current maturities | 1,639 | 1,796 | |||||
| Liability for employee rights upon retirement and others | 1,321 | 1,247 | |||||
| Total long-term liabilities | 2,960 | 3,043 | |||||
| Total liabilities | $ | 10,327 | $ | 10,721 | |||
| Equity: | |||||||
| Common stock, par value | 3 | 3 | |||||
| Preferred C shares, par value 1,172,000 shares authorized at March 31, 2025 and December 31, 2024; 1,718 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | * | * | |||||
| Additional paid-in capital | 293,014 | 289,589 | |||||
| Accumulated deficit | (264,672 | ) | (253,506 | ) | |||
| Total equity | 28,345 | 36,086 | |||||
| Total liabilities and equity | $ | 38,672 | $ | 46,807 | |||
(1) All 2025 financial information is derived from the Company’s 2025 unaudited financial statements, as disclosed in the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission; all 2024 financial information is derived from the Company’s 2024 unaudited financial statements, as disclosed in the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission.
(2) All March 31, 2025financial information is derived from the Company’s 2025 unaudited financial statements, as disclosed in the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission. All December 31, 2024 financial information is derived from the Company’s 2024 audited financial statements as disclosed in the Company’s Annual Report on Form 10-K, for the twelve months ended December 31, 2024 filed with the Securities and Exchange Commission.
FAQ
What were InspireMD's (NSPR) Q1 2025 revenue and earnings?
When does InspireMD expect FDA approval for CGuard Prime?
What is InspireMD's (NSPR) cash position as of Q1 2025?
Why did InspireMD's operating expenses increase in Q1 2025?
What is the status of InspireMD's CGUARDIANS II study?
